European Society for Medical Oncology Congress (ESMO) | Conference

Pembrolizumab Plus Lenvatinib May Serve as Potential Frontline Treatment for Non–Clear Cell RCC
October 05, 2022

Patients with locally advanced/metastatic non–clear cell renal cell carcinoma experienced promising preliminary antitumor activity following treatment with pembrolizumab and lenvatinib in the first line.

Despite Improving Responses, Pembrolizumab/Olaparib Fails to Improve Survival in mCRPC
September 29, 2022

Results from the phase 3 KEYLYNK-010 study showed that treatment with pembrolizumab and olaparib did not result in a statistically significant improvement in survival despite yielding higher responses compared with novel hormonal agents in patients with previously treated prostate cancer.

Nivolumab ± Ipilimumab Yields Meaningful, Durable Responses in Recurrent or Metastatic Cervical Cancer
September 28, 2022

The 24-month follow-up of the phase 1/2 CheckMate 358 trial found nivolumab with or without ipilimumab yielded clinically meaningful, long-lasting responses in patients with recurrent or metastatic cervical cancer.

Sacituzumab Govitecan Improved Outcomes in HR+/HER2– Metastatic Breast Cancer Vs Physician’s Choice
September 27, 2022

Results from a post-hoc subgroup analysis of the phase 3 TROPiCS-02 study indicated that sacituzumab govitecan improved efficacy outcomes vs physician’s choice of treatment in HER2-low and HER2 immunohistochemistry 0, hormone receptor–positive metastatic breast cancer.

Amit Oza, MD, MBBS, FRCPC, Discusses Optimizing Treatment With PARP Inhibitors in Advanced Ovarian Cancer
September 26, 2022

PARP inhibitors like rucaparib should be considered to treat all kinds of patients, including those who have deleterious mutations and HIV, according to Amit Oza, MD, MBBS, FRCPC.

Amit Oza, MD, MBBS, FRCPC, Highlights the Benefit of Early Maintenance PARP Inhibitor Use in Ovarian Carcinoma
September 23, 2022

PARP inhibitors such as rucaparib appear to garner the most benefit in the early maintenance setting in patients with ovarian cancer who have less advanced disease and less heterogeneity, according to Amit Oza, MD, MBBS, FRCPC.

Fred Saad, MD, FRCS, Highlights Positive OS Trend With Abiraterone and Olaparib in mCRPC But Cites Need for Longer Follow-up
September 22, 2022

Abiraterone and olaparib continued to demonstrate a positive trend in overall survival (OS) in patients with metastatic castration-resistant prostate cancer, according to Fred Saad, MD, FRCS, though he stated that longer follow-up is needed to confirm the benefit.

Stacey A. Cohen, MD, Discusses the Relevance of ctDNA as a Prognostic Marker for Resected Stage I-III CRC
September 16, 2022

Based on findings from a real-world retrospective analysis, Stacey A. Cohen, MD, discussed the prognostic value of post-surgical minimal residual disease detection in patients with stage I to III colorectal cancer.

Neoadjuvant Pegylated Lipsomal Doxorubicin/Cyclophosphamide Plus Trastuzumab/Pertuzumab Yields Promising Efficacy in HER2+ Breast Cancer
September 16, 2022

Findings from a phase 2 clinical study indicated that neoadjuvant pegylated liposomal doxorubicin plus cyclophosphamide, trastuzumab, and pertuzumab demonstrated promising efficacy and safety in the treatment of HER2-positive breast cancer.

Favorable Efficacy, Safety of Lenvatinib Plus Pembrolizumab Reported in Metastasized Anaplastic and Poorly Differentiated Thyroid Carcinoma
September 13, 2022

Final data from the phase 2 ATLEP trial showed high response rates with a combination of lenvatinib and pembrolizumab in patients with anaplastic and poorly differentiated thyroid cancer.